Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a progressive liver disease characterized by hepatic lipid accumulation, inflammation, and fibrosis, with progression risk toward cirrhosis and hepatocellular carcinoma (HCC). According to WHO, fatty liver disease affects a substantial proportion of the global population, making the development of effective pharmacotherapies a high-priority area for the pharmaceutical industry.

Among retrieved results, the farnesoid X receptor (FXR/NR1H4) is the most frequently cited primary therapeutic target, followed by thyroid hormone receptor beta (THRβ) and acetyl-CoA carboxylase (ACC/ACACA). The PatSnap life sciences platform captures patent and literature signals across all three modalities, enabling researchers to track IP activity in real time.

Several fibrosis-associated markers — including TGF-β1, α-SMA, collagen I (Col1a1), and TLR4 — appear as mechanistic endpoints across multiple patent filings, indicating that anti-fibrotic activity is a key efficacy criterion for these programs. A 2025 Chinese patent from the First Affiliated Hospital of Xinjiang Medical University further identifies PCSK9 as an emerging target in MASH, with PCSK9 knockout mice showing reduced hepatic lipid accumulation, inflammation, and fibrosis.

Academic literature retrieved highlights the gut-liver axis as central to FXR biology, noting that FXR is expressed in both the intestine and liver and that disruption of the Nrlh4 gene in mice leads to fatty liver formation under high-cholesterol feeding conditions, with FXR deficiency also increasing susceptibility to NASH in diet-induced obese models.

FXR agonist combination IP is densely populated. Intercept Pharmaceuticals, Novartis, Akarna Therapeutics, and Eli Lilly collectively claim broad combination spaces around FXR agonists. New entrants seeking to patent FXR + standard-of-care combinations face a crowded IP landscape and should evaluate freedom-to-operate carefully, particularly for obeticholic acid-adjacent strategies. The PatSnap analytics platform can help map white spaces in this crowded field.

THRβ agonist monotherapy IP may be less encumbered. In this dataset, THRβ agonists appear primarily as combination partners rather than as standalone compound patents, suggesting that the combination use space with FXR agonists (claimed by Terns Pharmaceuticals) is an area of active IP competition, while pure THRβ agonist chemistry may warrant separate investigation. According to FDA records, resmetirom's 2024 approval confirms the clinical validation of this target class.

ACC inhibitors are positioned as combination components. Retrieved results do not surface standalone ACC inhibitor MASH compound patents; they appear consistently as second agents in FXR combination regimens. This may indicate that the ACC inhibitor IP space for MASH is held upstream (compound-level) and that combination-use claims remain a defensible IP strategy for companies holding both assets.

The 2024 resmetirom approval reshapes competitive dynamics. Retrieved results explicitly frame the MASH competitive environment post-resmetirom approval, indicating that new entrants (including Chinese academic institutions pursuing PCSK9, AKR1C3, and novel pathway targets) are motivated to develop differentiated mechanisms rather than compete head-to-head with the first-approved THRβ agonist. The PatSnap customer case studies show how leading pharma organizations use IP intelligence to navigate exactly these post-approval competitive dynamics.

Chronotherapy and dosing optimization represent underexplored IP opportunities. Novartis' pending filings on evening administration of FXR agonists suggest that dosing regimen optimization is being pursued as a distinct IP strategy, potentially extending the commercial lifecycle of existing compounds with minimal chemical novelty requirements. Researchers can explore dosing-related patent claims via PatSnap Eureka's AI-powered search.